Skip to main content
MOA Life Plus Co. Ltd. logo

MOA Life Plus Co. Ltd. — Investor Relations & Filings

Ticker · 142760 ISIN · KR7142760008 KO Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2022-03-23 Audit Report / Informat…
Country KR South Korea
Listing KO 142760

About MOA Life Plus Co. Ltd.

http://moalifeplus.com/

MOA Life Plus Co. Ltd. is a biopharmaceutical company that researches and develops innovative medicines and consumer healthcare products. The company's pharmaceutical division focuses on a pipeline of biopharmaceuticals, including immunotherapies, cancer treatments, and vaccines for infectious diseases. A core platform technology utilizes Gamma-Polyglutamic Acid (γ-PGA), a natural amino acid polymer derived from fermented foods, to enhance immune responses and serve as a vaccine adjuvant. The consumer business division provides tailored healthcare solutions for immunity enhancement, skin rejuvenation, and pet care. It also manufactures and supplies γ-PGA-based raw materials for the cosmetics industry.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for BioLeaders, covering the fiscal year 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2021
2022-03-23 Korean
투자판단관련주요경영사항(중등증 코로나바이러스감염증-19 (COVID-19) 환자를 대상으로 BLS-H01의 유효성과 안전성을 평가하기 위한 다기관, 무작위배정, 이중눈가림, 위약 대조, 평행군, 제2상 임상시험 계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (BioLeaders) submitted to the Korea Exchange (KRX). It details the approval of a Phase 2 clinical trial for a COVID-19 treatment (BLS-H01) by the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into categories like financial reports, dividends, or shareholder meetings, it is classified as a general regulatory filing (RNS).
2022-03-22 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and is a regulatory filing submitted to the Financial Services Commission/Korea Exchange. It contains information regarding the solicitation of proxies for the company's Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and financial statements. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-18 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by BioLeaders. It outlines the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and articles of incorporation changes). This type of document is a standard proxy solicitation material provided to shareholders to inform them of upcoming meeting details and voting items, which falls under the Proxy Solicitation & Information Statement category.
2022-03-16 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by BioLeaders regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date despite participation in a voluntary dispersion program. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2022-03-16 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for BioLeaders Corp. It contains the agenda for the upcoming annual general meeting, including the approval of financial statements, election of directors, and remuneration limits. It also includes detailed financial statements (balance sheet, income statement, statement of changes in equity) as reference material for shareholders. This type of document is a standard Proxy Solicitation & Information Statement (PSI) used to inform shareholders of meeting details and solicit votes.
2022-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.